{"id":"https://openalex.org/W2885065879","doi":"https://doi.org/10.1002/ajh.25243","title":"Duvelisib, an oral dual PI3K\u2010\u03b4,\u03b3 inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study","display_name":"Duvelisib, an oral dual PI3K\u2010\u03b4,\u03b3 inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study","publication_year":2018,"publication_date":"2018-08-10","ids":{"openalex":"https://openalex.org/W2885065879","doi":"https://doi.org/10.1002/ajh.25243","mag":"2885065879","pmid":"https://pubmed.ncbi.nlm.nih.gov/30094870","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8260004"},"language":"en","primary_location":{"id":"doi:10.1002/ajh.25243","doi":"https://doi.org/10.1002/ajh.25243","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25243","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25243","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25243","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006104041","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0002-2481-7504","observed_orcids":["https://orcid.org/0000-0002-2481-7504"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Susan O'Brien","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, Texas"],"raw_orcid":"https://orcid.org/0000-0002-2481-7504","affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005718112","display_name":"Manish R. Patel","orcid":"https://orcid.org/0000-0001-6836-2364","observed_orcids":["https://orcid.org/0000-0001-6836-2364"]},"institutions":[{"id":"https://openalex.org/I4210138011","display_name":"Oncology Specialists of Charlotte","ror":"https://ror.org/039b8pv66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210138011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manish Patel","raw_affiliation_strings":["Florida Cancer Specialists, Sarasota, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists, Sarasota, Florida","institution_ids":["https://openalex.org/I4210138011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069054551","display_name":"Brad S. Kahl","orcid":"https://orcid.org/0000-0003-0459-6609","observed_orcids":["https://orcid.org/0000-0003-0459-6609"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brad S. Kahl","raw_affiliation_strings":["Washington University, St. Louis, Missouri"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University, St. Louis, Missouri","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069406522","display_name":"Steven Michael Horwitz","orcid":"https://orcid.org/0000-0002-6399-2006","observed_orcids":["https://orcid.org/0000-0002-6399-2006"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven M. Horwitz","raw_affiliation_strings":["Memorial Sloan-Kettering Cancer Center, New York, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan-Kettering Cancer Center, New York, New York","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048583088","display_name":"Francine M. Foss","orcid":"https://orcid.org/0000-0001-7843-3162","observed_orcids":["https://orcid.org/0000-0001-7843-3162"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francine M. Foss","raw_affiliation_strings":["Yale University Cancer Center, New Haven, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale University Cancer Center, New Haven, Connecticut","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041950455","display_name":"Pierluigi Porcu","orcid":"https://orcid.org/0000-0002-8056-023X","observed_orcids":["https://orcid.org/0000-0002-8056-023X"]},"institutions":[{"id":"https://openalex.org/I2802841970","display_name":"The Ohio State University Wexner Medical Center","ror":"https://ror.org/00c01js51","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pierluigi Porcu","raw_affiliation_strings":["The Ohio State University Wexner Medical Center, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University Wexner Medical Center, Columbus, Ohio","institution_ids":["https://openalex.org/I2802841970"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102896676","display_name":"Jeffrey Alan Jones","orcid":"https://orcid.org/0000-0001-9557-0820","observed_orcids":["https://orcid.org/0000-0001-9557-0820"]},"institutions":[{"id":"https://openalex.org/I2802841970","display_name":"The Ohio State University Wexner Medical Center","ror":"https://ror.org/00c01js51","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Jones","raw_affiliation_strings":["The Ohio State University Wexner Medical Center, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University Wexner Medical Center, Columbus, Ohio","institution_ids":["https://openalex.org/I2802841970"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058755419","display_name":"Jan A. Burger","orcid":"https://orcid.org/0000-0002-6177-7572","observed_orcids":["https://orcid.org/0000-0002-6177-7572"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jan Burger","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021380291","display_name":"Nitin Jain","orcid":"https://orcid.org/0000-0003-0114-8384","observed_orcids":["https://orcid.org/0000-0003-0114-8384"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nitin Jain","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009763835","display_name":"Kerstin R. Allen","orcid":"https://orcid.org/0009-0004-9286-6158","observed_orcids":["https://orcid.org/0009-0004-9286-6158"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerstin Allen","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kerrie Faia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerrie Faia","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074128964","display_name":"Mark Douglas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Douglas","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028575353","display_name":"Howard Marvin Stern","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard M. Stern","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112877054","display_name":"Jennifer Sweeney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Sweeney","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066471470","display_name":"Patrick Francis Kelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Kelly","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110640745","display_name":"Virginia M. Kelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Virginia Kelly","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian Flinn","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210100810"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5006104041"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":5450,"currency":"USD","value_usd":5450},"apc_paid":null,"fwci":3.8186,"has_fulltext":true,"cited_by_count":60,"citation_normalized_percentile":{"value":0.94409465,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"93","issue":"11","first_page":"1318","last_page":"1326"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duvelisib","display_name":"duvelisib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9769999980926514},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/relapsed-refractory-disease","display_name":"relapsed/refractory disease","score":0.9120000004768372},{"id":"https://openalex.org/keywords/del-17p-tp53-mutation","display_name":"del(17p)/TP53 mutation","score":0.906000018119812},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.6399999856948853},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8339999914169312},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.5799999833106995},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7929999828338623},{"id":"https://openalex.org/keywords/transaminase-elevation","display_name":"transaminase elevation","score":0.8429999947547913},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7260000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7965406179428101},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7570775747299194},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.748415470123291},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6529285311698914},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6314338445663452},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5682883262634277},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5318894982337952},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.5018208026885986},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.45342278480529785},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2021872103214264},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.1863844394683838}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000637","descriptor_name":"Transaminases","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009503","descriptor_name":"Neutropenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D015451","descriptor_name":"Leukemia, Lymphocytic, Chronic, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/ajh.25243","doi":"https://doi.org/10.1002/ajh.25243","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25243","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25243","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},{"id":"pmid:30094870","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30094870","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American journal of hematology","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:pubmedcentral.nih.gov:8260004","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8260004","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Am J Hematol","raw_type":"Text"},{"id":"pmh:oai:escholarship.org:ark:/13030/qt06r5f8q5","doi":null,"is_oa":true,"landing_page_url":"https://escholarship.org/uc/item/06r5f8q5","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Journal of Hematology, vol 93, iss 11","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/ajh.25243","doi":"https://doi.org/10.1002/ajh.25243","is_oa":true,"landing_page_url":"https://doi.org/10.1002/ajh.25243","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25243","source":{"id":"https://openalex.org/S199810014","display_name":"American Journal of Hematology","issn_l":"0361-8609","issn":["0361-8609","1096-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Journal of Hematology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G9000856728","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA008748","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320318998","display_name":"Verastem Oncology","ror":"https://ror.org/0562yk913"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2885065879.pdf","grobid_xml":"https://content.openalex.org/works/W2885065879.grobid-xml"},"referenced_works_count":40,"referenced_works":["https://openalex.org/W62641911","https://openalex.org/W197751408","https://openalex.org/W1497810503","https://openalex.org/W1525326448","https://openalex.org/W1553466143","https://openalex.org/W1977070803","https://openalex.org/W1984147944","https://openalex.org/W1995618664","https://openalex.org/W2011225907","https://openalex.org/W2024216962","https://openalex.org/W2025786205","https://openalex.org/W2026234361","https://openalex.org/W2026602389","https://openalex.org/W2037038519","https://openalex.org/W2052763184","https://openalex.org/W2056242938","https://openalex.org/W2070361307","https://openalex.org/W2070487917","https://openalex.org/W2071549499","https://openalex.org/W2095447519","https://openalex.org/W2096880409","https://openalex.org/W2103470187","https://openalex.org/W2106684817","https://openalex.org/W2120703403","https://openalex.org/W2124647461","https://openalex.org/W2131078883","https://openalex.org/W2134645992","https://openalex.org/W2134797116","https://openalex.org/W2136166312","https://openalex.org/W2142099365","https://openalex.org/W2145517536","https://openalex.org/W2154288461","https://openalex.org/W2171443164","https://openalex.org/W2231156824","https://openalex.org/W2337485820","https://openalex.org/W2560799488","https://openalex.org/W2563723939","https://openalex.org/W2775080684","https://openalex.org/W2775670706","https://openalex.org/W2980882408"],"related_works":["https://openalex.org/W2775670706","https://openalex.org/W4390273649","https://openalex.org/W3137375314","https://openalex.org/W2895287765","https://openalex.org/W2341725288","https://openalex.org/W2883482938","https://openalex.org/W2757924882","https://openalex.org/W4389229526","https://openalex.org/W2971066523","https://openalex.org/W4313585435"],"abstract_inverted_index":{"Duvelisib":[0,55],"(IPI-145),":[1],"an":[2],"oral,":[3],"dual":[4],"inhibitor":[5],"of":[6,66],"phosphoinositide-3-kinase":[7],"(PI3K)-\u03b4":[8],"and":[9,36,75,106,131,160],"-\u03b3,":[10],"was":[11,56,85,141,148,166],"evaluated":[12],"in":[13,18,26,61,69,78,144,171,176],"a":[14,52,172],"Phase":[15],"1":[16,157],"study":[17,175],"advanced":[19],"hematologic":[20],"malignancies,":[21],"which":[22],"included":[23],"expansion":[24],"cohorts":[25],"relapsed/refractory":[27],"(RR)":[28],"chronic":[29],"lymphocytic":[30,33],"leukemia":[31],"(CLL)/small":[32],"lymphoma":[34],"(SLL)":[35],"treatment-na\u00efve":[37],"(TN)":[38],"CLL.":[39],"Per":[40],"protocol,":[41],"TN":[42,79,116,134,152],"patients":[43,71,80,126,135,146],"were":[44,122],"at":[45,64],"least":[46],"65":[47],"years":[48],"old":[49],"or":[50],"had":[51],"del(17p)/TP53":[53],"mutation.":[54],"administered":[57],"twice":[58],"daily":[59],"(BID)":[60],"28-day":[62],"cycles":[63],"doses":[65],"8-75":[67],"mg":[68,77,164],"RR":[70,93,104,125,145,177],"(n":[72,81],"=":[73,82],"55)":[74],"25":[76,163],"18.)":[83],"Diarrhea":[84],"the":[86,97,108],"most":[87,98,109],"common":[88,110],"nonhematologic":[89],"AE":[90,101,113],"(TN":[91,102],"78%,":[92],"47%);":[94],"transaminase":[95],"elevations":[96],"frequent":[99],"lab-abnormality":[100],"33.3%,":[103],"30.9%);":[105],"neutropenia":[107],"\u2265grade":[111],"3":[112,174],"(RR":[114],"44%,":[115],"33%).":[117],"The":[118],"overall":[119],"response":[120,139],"rates":[121],"56.4%":[123],"for":[124,133,151,168],"(1.8%":[127],"CR,":[128],"54.5%":[129],"PR)":[130],"83.3%":[132],"(all":[136],"PRs);":[137],"median":[138],"duration":[140],"21.0":[142],"months":[143],"but":[147],"not":[149],"reached":[150],"patients.":[153],"Based":[154],"upon":[155],"phase":[156,173],"efficacy,":[158],"pharmacodynamics,":[159],"safety,":[161],"duvelisib":[162],"BID":[165],"selected":[167],"further":[169],"investigation":[170],"CLL/SLL.":[178]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-08-22T00:00:00"}